you, Thank Jennifer.
approved we Beyond lines patient of are opportunities the for the histologies. exploring into addressable expand to population treatment additional ZYNLONTA, first indication and into earlier
response pivotal updated and rate trial XX% presented the a response rate, As complete XX%. The at ICML. ZYNLONTA from were data was overall Chris ASCO and mentioned earlier, LOTIS-X
to months duration As response of all responses XXXX the increased responders, X, for date, median the XX.X March high-risk durable even with cut-off subgroups. in
for patients response of was duration median reached. the pre-responding not addition, In
and we cycle we've the encouraging hit of of decided respond Based the rate safety a XX% and did ibrutinib lymphoma, triple or population first-line of XX% reinforce response toxicity, in from As any overall LOTIS-X protocol trial the DLBCL, trial non-GCB hit interim potentially second-line presented expanding every to stem trial who and of ZYNLONTA Patients amend and of showed safety a the who therapy. rate therapy could a portion to cell relapsed DLBCL, administration. complete its pursue with in evaluate at of additional Updated data cell refractory benefit efficacy this DLBCL patients of enroll. to profile double or of on Phase the CAR-T prior with from reminder, patient monotherapy, ZYNLONTA. included combination not with potentially with this mantle ongoing efficacy convenient of and Phase patients in number those who subtype to therapy on enhance with continues with Based ICML of administration data, market ease the further manageable patients. a and transplant, for III lymphoma. in including and data study and this addressable B-cell II Phase patients These the failed efficacy ZYNLONTA results I patients or genetics. II trial, David or Phase durability. lines manageable a ZYNLONTA, recently an response to as could the The high-grade
in and rituximab, study stem in with Phase confirmatory the previously the relapsed/refractory year, continues filing in a DLBCL trial DLBCL multiple half an lymphoma, to in in relapsed ZYNLONTA second-line untreated trial as portion the dose-finding I, to umbrella in with expect trial or support some safety leading combinations LOTIS-X several ZYNLONTA of patients. combination second is B-cell complete including lymphoma This lines ZYNLONTA, of supplemental non-Hodgkin of Phase trial to for clinical cell combination There the and plans of non-Hodgkin of III additionals trial in BLA II R-CHOP into B-cell the These the II initiate the for half a earlier B-cell not for explore patients trial ongoing Pivotal as the intended in eligible moment is now a open well. for therapy trials of refractory in transplant. expansion relapsed/refractory year. will second the market this patients, enroll to therapy are lymphomas. we Our across in
based to As later mentioned, Europe the year in M&A LOTIS-X an plan data. on Chris file we this
Moving to Cami.
programs. or at Hodgkin interim and Phase of made in results II were Hodgkin enrollment reached, of safety was solid of trial ICML patient showed of a signals have complete lymphoma refractory an pivotal both, population response therapy. median We and XX% presented Median in and rate response pre-treated six in have been overall progress relapsed heavily a tumor rate We lines and completed our duration lymphoma. XXX XX% new identified. no our a systemic of not prior with response Updated
inhibitor. encouraged are providing cell need stem most checkpoint these have look continue transplant, which address these and whom highlight mature. by an to additional failed results and don't unmet pre-treated of data medical to potential We to have of need We updates whom heavily they all forward lymphoma a rituximab Hodgkin the as failed patients, in
our is in advance has Data combination patients with the in We trial ongoing also monotherapy dose tolerated which show that a to Phase continue Treg tumors. T with to patients effector at associated Cami increase T as encouraging anti-tumor also solid an pembrolizumab infiltration treatment ASCO It's safety of profile the in with to not tumors, Cami with reached. ratio advanced Ib dose in of encouraging thought was maximum see significant that effects. a showed escalation number to be Cami immunovant with presented with cell
with we Phase expect to exemplifies, a breast validated We the patients quarter, with higher first-in-class needs, program and tumors. the we is the this treatment solid of a the with in the accounting filed FDA in ADCT-XXX solid second a in cancer. the for of our tumors initiate platform triple-negative ADC cancer the treatment antigen deploying ovarian study resistant and As advanced which patients novel for ADCT-XXX, I the second platinum of half year. KAAGX, are IND targeting medical including candidate cleared,
glioma our and overexpress many such as candidates, is ADCT-XXX esophageal AXL, targeting which should pancreas, breast, Another lung, pipeline solitaires, cancer. of prostate, promising
the initiate first multiple combination tumors Phase half in We to study expect XXXX. the of Ib solid in
ADCT-XXX CDXX, with collaboration in I/II targeting enroll trial continues refractory relapsed a in patients lymphoblastic Phase acute In to program MD and addition, Anderson. leukemia our for
with will our six development we to give pre-clinical pipeline look updated that, forward you turn on financial Finally, the over we With to update. to and a robust I have call programs, keeping a R&D Jenn progress.
